Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CSL Behring
Pharma
CSL cuts FY26 revenue projection by $600M, writes off $5B
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion and is taking a $5 billion asset impairment.
Kevin Dunleavy
May 11, 2026 11:30am
CSL's Hemgenix in 'temporary global stockout,' company says
Mar 19, 2026 4:35pm
CSL firms up details on $1.5B US plasma-based medicines plant
Mar 10, 2026 10:30am
CSL details sales slide behind recent leadership transition
Feb 12, 2026 8:29am
Beleaguered CSL announces surprise CEO retirement
Feb 10, 2026 10:45am
ASH: CSL proves 5-year durability of Hemgenix
Dec 7, 2025 12:00pm
